ACONAclarion, Inc.

Nasdaq aclarion.com


$ 0.18 $ 0.00 (1.94 %)    

Friday, 06-Sep-2024 11:31:29 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 0.1835
$ 0.23 x 711
-- x --
-- - --
$ 0.18 - $ 9.90
1,091,940
na
1.58M
$ -5.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-25-2023 06-30-2023 10-Q
6 07-03-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 06-06-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aclarion-added-to-prism-emerging-medical-devices-index-cos-technology-addresses-chronic-low-back-pain-aclarion-secured-its-first-commercial-agreement-with-michigans-sheridan-community-hospital

Company's industry-first technology addresses chronic low back painAclarion secured its first commercial agreement with Mic...

 ascendiant-capital-maintains-buy-on-aclarion-lowers-price-target-to-15

Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and lowers the price target from $1.6 to $...

 aclarion-launches-the-clinical-utility-and-economic-trial-to-quantify-how-often-nociscans-ai-generated-biomarker-data-changes-surgical-treatment-plans

Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After R...

 aclarion-announces-first-commercial-agreement-in-michigan-sheridan-community-hospital-is-the-first-healthcare-institution-in-michigan-with-nociscan

Sheridan Community Hospital is the First Healthcare Institution in Michigan With NociscanAgreement Expands Nociscan Access to J...

 ascendiant-capital-initiates-coverage-on-aclarion-with-buy-rating-announces-price-target-of-16

Ascendiant Capital analyst Lucas Ward initiates coverage on Aclarion (NASDAQ:ACON) with a Buy rating and announces Price Tar...

 aclarion-has-been-granted-european-patent-ep3928695-titled-magnetic-resonance-spectroscopy-pulse-sequence-acquisition-and-processing-system-and-method-for-diagnosing-back-pain-such-as-low-back-pain-associated-with-degenerative-disc-disease

https://register.epo.org/application?number=EP21157092

Core News & Articles

Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)))), a healthcare technology company that is ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION